The reported revenue is in line with consensus estimates, which suggests that the market expectations have been met. The high adoption rate by new customers and the success of the Waterlase Trial Program could be seen as indicators of strong product demand and effective marketing, which may positively influence investor sentiment. The significant increase in consumable sales further demonstrates the company's growing market penetration and recurring revenue potential. These factors combined are likely to have a positive short-term impact on BIOL's stock price.